-
The import of sagebrush has decreased, and the long-term will continue to be optimistic!
Time of Update: 2022-08-19
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
-
Improvement of the pharmacovigilance system
Time of Update: 2022-08-19
In order to enhance the pharmacovigilance awareness of drug marketing authorization holders (hereinafter referred to as "holders"), the "Draft for Comments" proposes that if the holder or other units fail to comply with the pharmacovigilance quality management standard, the "Drug Administration Law" Article 126 stipulates punishment, which also forms an effective connection with China's pharmacovigilance inspection work .
-
Interpretation of the "14th Five-Year Plan for the Development of Health Talents"
Time of Update: 2022-08-19
Health and health work policy, follow the characteristics of the health and health industry and the law of talent growth, strengthen the concept of talent resources as the first resource, with the theme of promoting high-quality development, focusing on complementing weaknesses, and deepening the reform of the talent system and mechanism As the driving force, it provides strong talent support for accelerating the construction of a healthy China .
-
On August 15, 3 listed pharmaceutical companies disclosed their performance in the first half of the year, and 2 achieved growth!
Time of Update: 2022-08-19
79% year-on-year According to the 2022 semi-annual report of Chengda Pharmaceutical, the company achieved operating income of 217 million yuan in the first half of the year, a year-on-year increase of 11.
-
The growth rate of CXO industry performance is highly certain, and many pharmaceutical companies have launched equity incentive plans
Time of Update: 2022-08-19
On August 15, Zhaoyan New Drug released the 2022 A-share restricted stock incentive plan (draft) .
On August 15, Zhaoyan New Drug released the 2022 A-share restricted stock incentive plan (draft) .
On August 15, Zhaoyan New Drug released the 2022 A-share restricted stock incentive plan (draft) .
-
In the dispute over the consistency evaluation of generic drugs, these pharmaceutical companies have won the first over-evaluation
Time of Update: 2022-08-19
In recent years, with the promotion of policies such as the normalization of centralized procurement and the consistency evaluation of generic drugs, pharmaceutical companies are actively promoting the review work, and the competition is fierce .
-
The biopharmaceutical market is vast, and all localities are stepping up efforts to promote the development of the industry!
Time of Update: 2022-08-19
According to reports, in the next step, Haikou will introduce more flexible and precise support policies, build more platforms for cooperation and exchange, pay close attention to enterprise service guarantees, form an efficient and coordinated development of innovation chains and industrial chains, and support high-end, large-scale and intensive biopharmaceutical industries.
-
Yangzijiang Pharmaceutical Group: Helping enterprises to develop high-quality with intellectual property rights
Time of Update: 2022-08-19
The meeting emphasized that enterprises should attach great importance to the protection of intellectual property rights, strengthen the strategic deployment of enterprises, improve the construction of organizational structure, strengthen the team of professionals, strengthen the protection of the whole chain of intellectual property rights, actively monitor and attack, ensure the effective production of high-value patents, and help Building an innovative country .
-
Xinjiang Urgently Procures New Coronavirus Antiviral Drug Azvudine Tablets for Clinical Use
Time of Update: 2022-08-19
Hu Zhichun also said that in order to further strengthen the basic medical security of the people during the epidemic disposal period, and to meet the emergency treatment needs of people with negative nucleic acid tests in the closed and controlled areas but suffering from other diseases , Xinjiang has first set up "yellow code hospitals" in key epidemic cities.
-
Within a day, the pharmaceutical company announced that 2 drugs had achieved good news in clinical trials!
Time of Update: 2022-08-19
The announcement shows that the company's SAL0112 tablets have been approved by the State Food and Drug Administration to carry out a phase I clinical trial for adult obese or overweight patients for weight management indications .
-
Within two days, multiple pharmaceutical companies announced their transcripts, and 4 companies achieved double growth in revenue and net profit
Time of Update: 2022-08-19
15% On August 10, Lingrui Pharmaceutical released its 2022 semi-annual report, saying that in the first half of the year, the company's operating income increased by 10.
-
In the second half of the year, the deputy general managers of more than 7 pharmaceutical companies changed!
Time of Update: 2022-08-19
On August 11, *ST Yikang announced that Mr. Yan Xiaojia, the company's deputy general manager and secretary of the board of directors, applied for his resignation due to personal reasons .
-
The new batch of key monitoring drug catalogs may be on the way, and pharmaceutical companies will face big challenges!
Time of Update: 2022-08-19
In the notice issued by the National Health and Health Commission this time, it is required to strengthen the key monitoring of the use and management of rational drug use drugs, antimicrobial drugs, anti-tumor drugs, proton pump inhibitors, glucocorticoids, narcotic drugs, traditional Chinese medicine injections, etc.
-
The inflated pricing of drugs has been withdrawn from the Internet and the price has been rectified, which wakes up the industry's alarm!
Time of Update: 2022-08-19
[Pharmaceutical Network Industry News] On August 9, the National Medical Insurance Administration issued a Circular on the Circumstances of 3 Companies Falsely Increasing the Prices of Raw Materials and Raising Drug Prices to Get Funds.
-
Yesterday, a pharmaceutical company announced that it will gradually divest the generic drug business whose performance did not meet expectations
Time of Update: 2022-08-19
The future growth strategy of the pharmaceutical industry is an integrated platform for the medical beauty business and the R&D, production and sales of innovative drugs.
The future growth strategy of the pharmaceutical industry is an integrated platform for the medical beauty business and the R&D, production and sales of innovative drugs.
-
Notice on Holding a Training Course on the Proposed Revision of Pharmaceutical Packaging Materials Standards for the 2025 Edition of the Chinese Pharmacopoeia
Time of Update: 2022-08-19
In order to facilitate the production enterprises of drugs and pharmaceutical packaging materials and relevant inspection agencies to understand and master the standards in a timely manner, and make various technical preparations for the transition of the old and new standards as soon as possible, our commission will hold an online "China The 2025 edition of the Pharmacopoeia intends to formulate and revise the standard training course for pharmaceutical packaging materials.
-
In order to increase the layout of the traditional Chinese medicine industry, many pharmaceutical companies plan to acquire and merge!
Time of Update: 2022-08-19
Recently, Wanbangde said in an investor survey that in the future, the company's pharmaceutical manufacturing sector will focus on the traditional Chinese medicine industry, jointly develop traditional Chinese medicine products, sort out the existing 24 traditional Chinese medicine products and carry out secondary research and development, and will not rule out acquisitions and mergers to enrich traditional Chinese medicine.
-
A first look at the survival status of Indian generic drug giants
Time of Update: 2022-08-19
Due to the relatively low labor cost in India, the per capita efficacy of Indian generic drug giants is generally low, and the annual per capita sales are mostly between 100,000 and 150,000 US dollars.
-
Ready to go, local pharmaceutical companies speed up to go overseas!
Time of Update: 2022-08-19
On July 11, Huahai Pharmaceutical announced that the company's enalapril maleate tablet ANDA for the treatment of hypertension has been approved by the FDA, which means that the product can be produced and sold in the US market .
-
In order to develop the main business, another pharmaceutical company sells a house!
Time of Update: 2022-08-19
According to the announcement of Foci Pharmaceuticals, in order to effectively revitalize the company's existing assets, focus on the main business of pharmaceuticals, and reduce the company's financial pressure, the company plans to transfer two lands located in Anning District, Lanzhou City to the controlling shareholder Foci Pharmaceutical Group at a price of 103 million yuan .
